AstraZeneca resumes clinical trials for COVID-19 vaccine aft
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Late-stage clinical trials of a COVID-19 vaccine being developed by the drug firm AstraZeneca and the University of Oxford have resumed.

Earlier this week, the firm had announced that it was putting a halt on the clinical trials.

• 'UK committee concluded trials are safe to resume'

AstraZeneca said on Saturday, "Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so."

The statement added, "The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume."

• AstraZeneca said it cannot disclose further medical information

AstraZeneca said that neither it nor Oxford University can disclose further medical information. "All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," the firm said.

• Trials were halted after volunteer fell ill

On Tuesday, it was announced that the clinical trials for AZD1222 had been halted. Reportedly, a trial volunteer had fallen ill after receiving the potential vaccine.

Thereafter, the Pune-based Serum Institute of India (SII) had also paused the vaccine's combined phase 2 and 3 clinical trials in India.

The Drugs Controller General of India (DCGI) had also asked SII to suspend recruitment in clinical trials.

Dr. M●●●●●●●h A●●m and 3 others like this4 shares